Advertisement

Healthcare Providers Underestimate Patients’ Glucocorticoid Use in Crohn’s Disease

  • Subrata GhoshEmail author
  • Brian Bressler
  • Jill Petkau
  • Roopal B. Thakkar
  • Song Wang
  • Martha Skup
  • Jingdong Chao
  • Remo Panaccione
  • Stefan Schreiber
Original Article
  • 40 Downloads

Abstract

Background

One of the therapy goals for Crohn’s disease (CD) is glucocorticoid-free remission. Studies have shown care setting-specific variations in inflammatory bowel disease (IBD) management.

Aims

The principal objective of this study was to assess concordance between patient-reported and physician-reported outcomes in two different care settings (IBD centers and community practices).

Methods

Data of overall and long-term (≥ 3 months) glucocorticoid, immunosuppressant, and biologics use in participants ≥ 18 years old with a confirmed diagnosis of CD were collected. HCPs were grouped by IBD centers and community practices. Quality of life (using EuroQol 5D [EQ-5D]) and work/activity days lost were assessed. Agreement between patients’ and HCPs’ responses to survey questions was tested using kappa statistics.

Results

Data from 812 patients were examined. Significantly more patients versus HCPs reported oral glucocorticoid use (25.9% vs. 20.8%, κ = 0.735, P < 0.0001). Long-term use of oral glucocorticoids was similar for patients versus HCPs (67.7% vs. 63.8%, κ = 0.598, P = 0.53). Immunosuppressant use was 52.4% vs. 51.1% (κ = 0.784) and biologics use was 49.5% vs. 47.0% (κ = 0.909) for patients vs. HCPs. Patients and HCPs reported greater rates of symptom improvement with vs without biologic therapy (patients: 33.3% vs 16.8%; HCPs: 29.3% vs 13.5%, both P < 0.001). Patients with versus without routine follow-up were less likely to be treated with long-term glucocorticoid monotherapy (10.3% vs. 20.7%, P < 0.01) and had fewer lost work/activity days (5 vs. 8 days, P < 0.05).

Conclusions

Patients reported more oral glucocorticoid use than physicians thought. Routine follow-up and higher rates of biologic use are associated with improvement in disease symptoms and general health among patients with CD.

Keywords

Crohn’s disease Glucocorticoids Patient-reported outcomes Physician-reported outcomes Quality of life 

Notes

Acknowledgments

Writing support was provided by Joann Hettasch, Ph.D., of Fishawack Facilitate Ltd, Conshohocken, PA, and was funded by AbbVie, Inc., North Chicago, IL.

Author’s contribution

S. Ghosh planned and conducted the study, collected data, reviewed the manuscript, made substantial content suggestions, and approved the final draft. B. Bressler conducted the study, collected data, interpreted data, reviewed the manuscript, made substantial content suggestions, and approved the final draft. J. Petkau conducted the study, collected data, interpreted data, reviewed the manuscript, made substantial content suggestions, and approved the final draft. R. B. Thakkar interpreted data, reviewed the manuscript, made substantial content suggestions, and approved the final draft. M. Skup conducted the data analyses, interpreted data, reviewed the manuscript, made substantial content suggestions, and approved the final draft. S. Wang conducted the data analyses, interpreted data, reviewed the manuscript, made substantial content suggestions, and approved the final draft. J. Chao conducted the data analyses, interpreted data, reviewed the manuscript, made substantial content suggestions, and approved the final draft. R. Panaccione conducted the study, collected data, interpreted data, reviewed the manuscript, made substantial content suggestions, and approved the final draft. S. Schreiber conducted the study, collected data, interpreted data, reviewed the manuscript, made substantial content suggestions, and approved the final draft.

Funding

This study was funded in full by AbbVie, North Chicago, Illinois, which is represented by R. Thakkar, S. Wang, M. Skup, and J. Chao. AbbVie was involved in developing the study concept and participated in the analysis and interpretation of the data; preparation, review, and approval of the manuscript; and decision to submit the manuscript for publication.

Compliance with ethical standards

Conflict of interest

S. Ghosh has served on ad hoc advisory boards of AbbVie, Merck, Shire, Pfizer, Receptos, Novo-Nordisk, Bristol-Myers Squibb, and Janssen. He has received honoraria for lecturing in educational events from AbbVie, Merck, Janssen, Takeda, and Shire and has received research support from AbbVie and Merck. B. Bressler is a consultant for AbbVie, Actavis, Jansen, Shire, Genentech, Takeda, Pendopharm, Celltrion; served on the Speaker’s Bureau for AbbVie, Jansen, Takeda, Shire, Ferring, Actavis; received research/educational support from AbbVie, Jansen, Millenium, Bristol-Myers Squibb, Amgen, GSK, Genentech, Celgene, AstraZeneca, RedHill Biopharma, Alvine, and BI, and has stock options from Qu Biologics. J Petkau has nothing to disclose. RB Thakkar and M Skup are employees of AbbVie and may hold stock. J Chao and S Wang were employees of AbbVie at the time of research and may own AbbVie stock. R Panaccione served as a consultant for AbbVie, Amgen, Aptalis, AstraZeneca, Baxter, Eisai, Ferring, Jansen, Merck, Schering-Plough, Shire, Centocor, Elan, Glaxo-Smith Kline, UCB, Pfizer, Bristol-Myers Squibb, Warner Chilcott; served on the Speaker’s Bureau for AbbVie, AstraZeneca, Jansen, Schering-Plough, Shire, Centocor, Elan, Prometheus, and Warner Chilcott; served on advisory boards for AbbVie, Amgen, Aptalis, AstraZeneca, Baxter, Eisai, Ferring, Jansen, Merck, Schering-Plough, Shire, Centocor, Elan, Glaxo-Smith Kline, UCB, Pfizer, Bristol-Myers Squibb, Warner Chilcott; and received research/educational support from AbbVie, Ferring, Jansen, Schering-Plough, Centocor, Millenium, Elan, Proctor and Gamble, and Bristol-Myers Squibb. S Schreiber served as study investigator and consultant for AbbVie and has participated in continuing medical education events supported by unrestricted educational grants from AbbVie. He has also served as a consultant and as a lecturer for Centocor/MSD, Schering-Plough, UCB, and Shire.

Ethical statement

The study protocol was approved by independent Medical Research Ethics Committees in agreement with local legal requirements in Canada and Germany. All patients provided written informed consent before participating in the study. Consenting patients were also asked to sign and date a form indicating that they were willing to have their HCP supply additional information about their condition and their current and previous CD treatment. To protect disclosure of patient identities, a unique identification number was assigned to each patient before collection of data; this identification number was used on both the patient and HCP questionnaires. No patient identifiable information was included in any of the information collected.

Supplementary material

10620_2018_5419_MOESM1_ESM.pdf (533 kb)
Supplementary material 1 (PDF 532 kb)
10620_2018_5419_MOESM2_ESM.pdf (785 kb)
Supplementary material 2 (PDF 784 kb)

References

  1. 1.
    Schirbel A, Reichert A, Roll S, et al. Impact of pain on health-related quality of life in patients with inflammatory bowel disease. World J Gastroenterol. 2010;16:3168–3177.CrossRefGoogle Scholar
  2. 2.
    Ghosh S, Mitchell R. Impact of inflammatory bowel disease on quality of life: results of the European Federation of Crohn’s and Ulcerative Colitis Associations (EFCCA) patient survey. J Crohns Colitis. 2007;1:10–20.CrossRefGoogle Scholar
  3. 3.
    Cohen RD. The quality of life in patients with Crohn’s disease. Aliment Pharmacol Ther. 2002;16:1603–1609.CrossRefGoogle Scholar
  4. 4.
    Casellas F, López-Vivancos J, Vergara M, Malagelada J. Impact of inflammatory bowel disease on health-related quality of life. Dig Dis. 1999;17:208–218.  https://doi.org/10.1159/000016938 CrossRefPubMedGoogle Scholar
  5. 5.
    Bernklev T, Jahnsen J, Henriksen M, et al. Relationship between sick leave, unemployment, disability, and health-related quality of life in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2006;12:402–412.CrossRefGoogle Scholar
  6. 6.
    Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142:46–54.CrossRefGoogle Scholar
  7. 7.
    Lichtenstein GR, Hanauer SB, Sandborn WJ. Practice parameters committee of American College of Gastroenterology. Management of Crohn’s disease in adults. Am J Gastroenterol. 2009;104:465–483.CrossRefGoogle Scholar
  8. 8.
    Deepak P, Loftus EV. Ustekinumab in treatment of Crohn’s disease: design, development, and potential place in therapy. Drug Des Dev Ther. 2016;10:3685–3698.CrossRefGoogle Scholar
  9. 9.
    Ge WS, Fan JG. Integrin antagonists are effective and safe for Crohn’s disease: a meta-analysis. World J Gastroenterol. 2015;21:4744–4749.CrossRefGoogle Scholar
  10. 10.
    Lichtenstein GR, Abreu MT, Cohen R, Tremaine W, American Gastroenterological Association. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology. 2006;130:940–987.CrossRefGoogle Scholar
  11. 11.
    Gross V, Andus T, Caesar I, et al. Oral pH-modified release budesonide vs. 6-methylprednisolone in active Crohn’s disease. German/Austrian Budesonide Study Group. Eur J Gastroenterol Hepatol. 1996;8:905–909.PubMedGoogle Scholar
  12. 12.
    Rutgeerts P, Lofberg R, Malchow H, et al. A comparison of budesonide with prednisolone for active Crohn’s disease. N Engl J Med. 1994;331:842–845.CrossRefGoogle Scholar
  13. 13.
    Munkholm P, Langholz E, Davidsen M, Binder V. Frequency of glucocorticoid resistance and dependency in Crohn’s disease. Gut. 1994;35:360–362.CrossRefGoogle Scholar
  14. 14.
    Malchow H, Ewe K, Brandes JW, et al. European Cooperative Crohn’s Disease Study (ECCDS): results of drug treatment. Gastroenterology. 1984;86:249–266.PubMedGoogle Scholar
  15. 15.
    Summers RW, Switz DM, Sessions JT Jr, et al. National cooperative Crohn’s disease study: results of drug treatment. Gastroenterology. 1979;77:847–869.PubMedGoogle Scholar
  16. 16.
    Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn’s disease: TREAT registry. Clin Gastroenterol Hepatol. 2006;4:621–630.CrossRefGoogle Scholar
  17. 17.
    Schoon EJ, Bollani S, Mills PR, et al. Bone mineral density in relation to efficacy and side effects of budesonide and prednisolone in Crohn’s disease. Clin Gastroenterol Hepatol. 2005;3:113–121.CrossRefGoogle Scholar
  18. 18.
    Rutgeerts PJ. The limitations of corticosteroid therapy in Crohn’s disease. Aliment Pharmacol Ther. 2001;15:1515–1525.CrossRefGoogle Scholar
  19. 19.
    Gurwitz JH, Bohn RL, Glynn RJ, Monane M, Mogun H, Avorn J. Glucocorticoids and the risk for initiation of hypoglycemic therapy. Arch Intern Med. 1994;154:97–101.CrossRefGoogle Scholar
  20. 20.
    Lukert BP, Raisz LG. Glucocorticoid-induced osteoporosis. Rheum Dis Clin North Am. 1994;20:629–650.PubMedGoogle Scholar
  21. 21.
    Stuck AE, Minder CE, Frey FJ. Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis. 1989;11:954–963.CrossRefGoogle Scholar
  22. 22.
    Whitworth JA. Mechanisms of glucocorticoid-induced hypertension. Kidney Int. 1987;31:1213–1224.CrossRefGoogle Scholar
  23. 23.
    Singleton JW, Law DH, Kelley ML Jr, Mekhjian HS, Sturdevant RA. National Cooperative Crohn’s Disease Study: adverse reactions to study drugs. Gastroenterology. 1979;77:870–882.PubMedGoogle Scholar
  24. 24.
    Cassinotti A, Keshav S, Ardizzone S, et al. IBD care in Europe: a comparative audit of the inpatient management of Crohn’s disease and ulcerative colitis using the national UK IBD audit tool. J Crohns Colitis. 2009;3:291–301.CrossRefGoogle Scholar
  25. 25.
    Colletti RB, Baldassano RN, Milov DE, et al. Variation in care in pediatric Crohn disease. J Pediatr Gastroenterol Nutr. 2009;49:297–303.CrossRefGoogle Scholar
  26. 26.
    Esrailian E, Spiegel BMR, Targownik LE, Dubinsky MC, Targan SR, Gralnek IM. Differences in the management of Crohn’s disease among experts and community providers, based on a national survey of sample case vignettes. Aliment Pharmacol Ther. 2007;26:1005–1018.CrossRefGoogle Scholar
  27. 27.
    Reddy SI, Friedman S, Telford JJ, Strate L, Ookubo R, Banks PA. Are patients with inflammatory bowel disease receiving optimal care? Am J Gastroenterol. 2005;100:1357–1361.CrossRefGoogle Scholar
  28. 28.
    Raspe H, Conrad S, Muche-Borowski C. Evidence-based and consented pathways for patients with inflammatory bowel diseases (IBD). Z Gastroenterol. 2009;47:541–562.CrossRefGoogle Scholar
  29. 29.
    Pickard AS, Neary MP, Cella D. Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer. Health Qual Life Outcomes. 2007;5:70.CrossRefGoogle Scholar
  30. 30.
    Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159–174.CrossRefGoogle Scholar
  31. 31.
    Dignass A, Van Assche G, Lindsay JO, et al. The second European evidence-based consensus on the diagnosis and management of Crohn’s disease: Current management. J Crohn’s Colitis. 2010;4:28–62.CrossRefGoogle Scholar
  32. 32.
    American Gastroenterological Association. Adult inflammatory bowel disease physician performance measures set: American gastroenterological association; 2011. Available at: https://download.ama-assn.org/resources/doc/pcpi/inflammatory-bowel-disease.pdf. Accessed Aug 20, 2015.
  33. 33.
    IBD Standards Group. Quality care service standards for the healthcare of people who have inflammatory bowel disease (IBD). St Albans: Oyster Healthcare Communications Ltd.; 2009. Available at: www.bsg.org.uk/attachments/160_IBDstandards.pdf. Accessed Aug 20, 2015.
  34. 34.
    Ricci C, Lanzarotto F, Lanzini A. The multidisciplinary team for management of inflammatory bowel diseases. Dig Liver Dis. 2008;40:S285–S288.CrossRefGoogle Scholar
  35. 35.
    Mawdsley JE, Irving PM, Makins RJ, Rampton DS. Optimizing quality of outpatient care for patients with inflammatory bowel disease: the importance of specialist clinics. Eur J Gastroenterol Hepatol. 2006;18:249–253.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Subrata Ghosh
    • 1
    • 2
    Email author
  • Brian Bressler
    • 3
  • Jill Petkau
    • 4
  • Roopal B. Thakkar
    • 5
  • Song Wang
    • 5
  • Martha Skup
    • 5
  • Jingdong Chao
    • 5
  • Remo Panaccione
    • 2
  • Stefan Schreiber
    • 6
  1. 1.NIHR Biomedical Research CentreUniversity of Birmingham and University Hospitals Birmingham NHS Foundation Trust, Institute of Translational MedicineBirminghamUK
  2. 2.University of CalgaryCalgaryCanada
  3. 3.University of British ColumbiaVancouverCanada
  4. 4.Alberta Health ServicesCalgaryCanada
  5. 5.AbbVie Inc.North ChicagoUSA
  6. 6.Christian-Albrechts UniversityKielGermany

Personalised recommendations